Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil: Is it time to move forward?
暂无分享,去创建一个
S. Kern | C. Yeo | T. Showalter | S. Showalter | J. Brody | T. Hucl | E. Kennedy | Agneszka Witkiewicz | R. Havens
[1] B. Wolpin,et al. Systemic treatment of colorectal cancer. , 2008, Gastroenterology.
[2] S. Kern,et al. Distinguishing Rational from Irrational Applications of Pharmacogenetic Synergies from the Bench to Clinical Trials , 2007, Cell cycle.
[3] J. Robert,et al. Involvement of gene polymorphisms of thymidylate synthase in gene expression, protein activity and anticancer drug cytotoxicity using the NCI-60 panel. , 2007, European journal of cancer.
[4] N. Koide,et al. Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes , 2007, Scandinavian journal of gastroenterology.
[5] S. Kern,et al. Targeting Fanconi Anemia/BRCA2 Pathway Defects in Cancer: The Significance of Preclinical Pharmacogenomic Models , 2007, Clinical Cancer Research.
[6] M. Roh,et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] M. Shimizu,et al. Simple combinations of 5‐FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S‐1 , 2006, International Journal of Cancer.
[8] S. Kern,et al. Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy. , 2006, Cancer research.
[9] R. Diasio,et al. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] C. V. D. van de Velde,et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.
[11] E. Giovannetti,et al. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer , 2006, Molecular Cancer Therapeutics.
[12] R. Hruban,et al. A proposed clinical test for monitoring fluoropyrimidine therapy: Detection and stability of thymidylate synthase ternary complexes , 2006, Cancer biology & therapy.
[13] Sunkyu Kim,et al. Validating cancer drug targets , 2006, Nature.
[14] M. Sarbia,et al. The prognostic significance of genetic polymorphisms (Methylenetetrahydrofolate Reductase C677T, Methionine Synthase A2756G, Thymidilate Synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma , 2005, British Journal of Cancer.
[15] D. Aust,et al. Immunohistochemical Analysis of Thymidylate Synthase, Thymidine Phosphorylase, and Dihydropyrimidine Dehydrogenase in Rectal Cancer (cUICC II/III): Correlation With Histopathologic Tumor Regression After 5-Fluorouracil-Based Long-Term Neoadjuvant Chemoradiotherapy , 2005, The American journal of surgical pathology.
[16] Maria Paola Costi,et al. Thymidylate synthase structure, function and implication in drug discovery. , 2005, Current medicinal chemistry.
[17] Yoshiro Saito,et al. Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents , 2005, Cancer Chemotherapy and Pharmacology.
[18] A. Jakobsen,et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Wooin Lee,et al. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. , 2005, The oncologist.
[20] Y. Kodera,et al. Expression level of thymidylate synthase is a good predictor of chemosensitivity to 5-fluorouracil in colorectal cancer , 2005, Journal of Gastroenterology.
[21] M. Baiget,et al. Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil‐based chemotherapy in advanced colorectal cancer patients , 2004, International journal of cancer.
[22] Kevin M. Ryan,et al. Mechanistic and Predictive Profiling of 5-Fluorouracil Resistance in Human Cancer Cells , 2004, Cancer Research.
[23] W. Schmidt,et al. Dissecting progressive stages of 5‐fluorouracil resistance in vitro using RNA expression profiling , 2004, International journal of cancer.
[24] D. Tregouet,et al. Thymidylate Synthase Gene Polymorphism Predicts Toxicity in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy , 2004, Clinical Cancer Research.
[25] A. Paradiso,et al. Topoisomerase‐I, thymidylate synthase primary tumour expression and clinical efficacy of 5‐FU/CPT‐11 chemotherapy in advanced colorectal cancer patients , 2004, International journal of cancer.
[26] S. Kern,et al. Stagnation and herd mentality in the biomedical sciences , 2004, Cancer biology & therapy.
[27] K. Danenberg,et al. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test. , 2005, Cancer letters.
[28] F. Kaye,et al. Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. , 2004, Cancer cell.
[29] G. Parmigiani,et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[30] M. Lucock,et al. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. , 2004, Journal of the National Cancer Institute.
[31] M. Ratain,et al. Pharmacogenetics in cancer treatment. , 2003, Annual review of medicine.
[32] M. Kornmann,et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[33] G. Watanabe,et al. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. , 2003, Cancer research.
[34] H. Pitt,et al. Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[35] P. Johnston,et al. 5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.
[36] R. Fujii,et al. Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma , 2003, International Journal of Clinical Oncology.
[37] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[38] P. Catalano,et al. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] W. Ichikawa,et al. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[40] S. Barni,et al. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[41] G. Peters,et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. , 2002, Biochimica et biophysica acta.
[42] S. Groshen,et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] G. Peters,et al. Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[44] S. Stryker,et al. Molecular markers and prediction of response to chemoradiation in rectal cancer. , 2001, Oncology reports.
[45] A. Monks,et al. Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[46] J. García-Foncillas,et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] F. Maley,et al. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[48] J. Grem. 5-Fluorouracil: Forty-Plus and Still Ticking. A Review of its Preclinical and Clinical Development , 2000, Investigational New Drugs.
[49] S. Barni,et al. Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[50] K. Danenberg,et al. Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy , 2000, Cancer.
[51] S. Groshen,et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[52] H. Blomgren,et al. Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[53] S. Barni,et al. Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[54] F. Maley,et al. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] Dm Thomas,et al. 5‐FLUOROURACIL: A PHARMACOLOGICAL PARADIGM IN THE USE OF CYTOTOXICS , 1998, Clinical and experimental pharmacology & physiology.
[56] J. Lokich. Infusional 5-FU: historical evolution, rationale, and clinical experience. , 1998, Oncology.
[57] S. Groshen,et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[58] P. Johnston,et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[59] S. Groshen,et al. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[60] S. Groshen,et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] H. Lenz,et al. Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. , 1997, Cancer letters.
[62] M. Ratain,et al. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. , 1997, Journal of the National Cancer Institute.
[63] Jürg Zimmermann,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.
[64] N. Horie,et al. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. , 1995, Cell structure and function.
[65] S. Steinberg,et al. Thymidylate synthase protein expression: Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma. , 1995, The cancer journal from Scientific American.
[66] J. P. Pignon,et al. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators , 1995, The Lancet.
[67] P. Johnston,et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. , 1995, Cancer research.
[68] H E Rockette,et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] S. Meijer,et al. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] P. Johnston,et al. Immunological quantitation of thymidylate synthase‐FdUMP‐5,10‐methylenetetrahydrofolate ternary complex with the monoclonal antibody TS 106 , 1993, Anti-cancer drugs.
[71] F. Berger,et al. Functional effects of a naturally occurring amino acid substitution in human thymidylate synthase. , 1993, Molecular pharmacology.
[72] S. T. Davis,et al. Variation in human thymidylate synthase is associated with resistance to 5-fluoro-2'-deoxyuridine. , 1993, Molecular pharmacology.
[73] P. Johnston,et al. Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma. , 1993, Advances in experimental medicine and biology.
[74] P. Johnston,et al. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. , 1992, Cancer research.
[75] P. Johnston,et al. Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. , 1991, Cancer research.
[76] P. Danenberg,et al. Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthetase. , 1981, Biochemical pharmacology.
[77] Amanda,et al. Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts. , 1980, The Journal of biological chemistry.
[78] P. Danenberg,et al. Thymidylate synthetase and 2'-deoxyuridylate form a tight complex in the presence of pteroyltriglutamate. , 1979, The Journal of biological chemistry.
[79] D. Santi,et al. Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5-fluoro-2'-deoxyuridylate and methylenetetrahydrofolate. , 1974, Biochemical and biophysical research communications.
[80] D. Santi,et al. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. , 1974, Biochemistry.
[81] D. Santi,et al. 5-Fluoro-2'-deoxyuridylate: covalent complex with thymidylate synthetase. , 1972, Proceedings of the National Academy of Sciences of the United States of America.
[82] C. Heidelberger,et al. Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory Compounds , 1957, Nature.
[83] G. Peters,et al. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[84] H. Lenz,et al. Pharmacogenomics and colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[85] O. Belvedere,et al. Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[86] M. Yin,et al. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] J. Bertino,et al. Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] S. Groshen,et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] V. Torri. Fluorouracil and folinic acid in colon cancer , 1996 .
[90] D. Santi,et al. The catalytic mechanism and structure of thymidylate synthase. , 1995, Annual review of biochemistry.
[91] R. Diasio,et al. Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. , 1993, Cancer investigation.